CN102786462A - Arbidol hydrochloride crystal B, its preparation method, and its applications in medicines and healthcare products - Google Patents
Arbidol hydrochloride crystal B, its preparation method, and its applications in medicines and healthcare products Download PDFInfo
- Publication number
- CN102786462A CN102786462A CN2011101285071A CN201110128507A CN102786462A CN 102786462 A CN102786462 A CN 102786462A CN 2011101285071 A CN2011101285071 A CN 2011101285071A CN 201110128507 A CN201110128507 A CN 201110128507A CN 102786462 A CN102786462 A CN 102786462A
- Authority
- CN
- China
- Prior art keywords
- hydrochloride
- arbidol
- monohydrate crystal
- type
- arbidol hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an Arbidol hydrochloride monohydrate crystal B substance with the structure represented by formula (I), a preparation method of an Arbidol hydrochloride monohydrate crystal B sample, and products prepared through treating the Arbidol hydrochloride monohydrate crystal B substance as an active component, and applications of the Arbidol hydrochloride monohydrate crystal B in the disease control and the healthcare, wherein the products comprise medicines and healthcare products.
Description
Technical field
The present invention relates to a kind of crystal B-type state of matter of Arbidol hydrochloride hydrochloride monohydrate; The preparation method of Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample; Adopt the product of Arbidol hydrochloride hydrochloride monohydrate crystal B-type material as activeconstituents; And the purposes of Arbidol hydrochloride hydrochloride monohydrate crystal B-type, belong to medical technical field.
Background technology
The Arbidol hydrochloride hydrochloride, English Arbidol hydrochloride by name, molecular structure is suc as formula shown in (I)
Arbidol hydrochloride is by FSU's pharmaceutical chemistry research centre development; Went on the market in Russia in 1993; Be used to prevent and treat influenza and other acute respiratory virus infections that A, Type B influenza virus cause, and can stop the complication of influenza virus to take place, have no side effect; Belong to the antiviral of wide spectrum, be interferon inducer and immunostimulant
[1-3]
The Arbidol hydrochloride drug effect is through activating 2, and 5-oligo-adenylate synthetase and specificity suppress the fusion of virus envelope and host's fine film and block duplicating of influenza virus
[4]
Find that through the Chinese patent retrieval existing patent majority is the protection to Arbidol hydrochloride different dosage form or compound and purposes:
In Chinese patent CN 1589790A (publication number), put down in writing Zhongqi Pharmaceutical Technology's invention " Arbidol hydrochloride slow releasing tablet and preparation method thereof "
[5]Wherein relate to the slow releasing tablet of having invented a kind of antiviral, it is prepared into hydrogel matrix slow releasing tablet and wax matrix sustained release tablet, invented the preparation method of these two kinds of sustained release preparations simultaneously through utilizing the water-fast characteristic of Arbidol hydrochloride.
In Chinese patent CN 1868470A (publication number), put down in writing " Abiduoer granular formulation " of Baili Pharmaceutical Co., Ltd., Sichuan Prov.'s invention
[6]It relates to has invented a kind of Abiduoer granular formulation.
In Chinese patent CN 101904826A (publication number), put down in writing Li Weidong invention " arbidol HCl orally disintegrating tablet and preparation method thereof "
[7]It relates to invented arbidol HCl a kind of and absorbs fast and orally disintegrating tablet that bioavailability is high and preparation method thereof.
In Chinese patent CN 101653425A (publication number), put down in writing SHANDONG LUOXIN PHARMACY STOCK Co., LTD.'s invention " a kind of arbidol hydrochloride medicament composition dispersible tablets and preparation method thereof "
[8]It relates to has invented all arbidol HCl compsn dispersible tablets and preparation method thereof preferably of a kind of substrate's appearance, hardness and dispersing uniformity.
In Chinese patent CN 1792362A (publication number), put down in writing " intravenous administration formulation of Arbidol hydrochloride and salt thereof and preparation method " that Shi Xiulan, Xu Hua invent
[9]It relates to the method for the intravenous administration formulation of having invented preparation Arbidol hydrochloride or its salt, and the application of this intravenous administration formulation aspect resisiting influenza virus.
In Chinese patent CN 1535680A (publication number), put down in writing " the Arbidol hydrochloride inclusion compound " of Zhongqi Pharmaceutical Technology's invention
[10]It relates to has invented a kind of new Arbidol hydrochloride and the molecular clathrate of Schardinger dextrins or its verivate, and the preparation method of this inclusion compound and their application in pharmaceutical prepn.
In Chinese patent CN 1572298A (publication number), put down in writing " compound preparation that contains Arbidol hydrochloride " of Zhongqi Pharmaceutical Technology's invention
[11]It relates to the compound preparation of having invented a kind of Arbidol hydrochloride, and this compound preparation medicine is applicable to the due to illness malicious respiratory infection diseases that causes.
In Chinese patent CN 1839829A (publication number), put down in writing " antiviral cold compound formulation that contains Arbidol hydrochloride and taurine " of Shi Xiulan invention
[12]It relates to has invented a kind of antiviral cold compound formulation and application thereof that contains Arbidol hydrochloride and taurine.
In Chinese patent CN 1546019A (publication number), put down in writing " a kind of compound Arbidol hydrochloride broad-spectrum antiviral cold medicine " of Li Xin invention
[13]It relates to has invented a kind of compound Arbidol hydrochloride broad-spectrum antiviral cold medicine of mainly being made up of Arbidol hydrochloride, PARACETAMOL BP98 and Toldrin or LT.
In Chinese patent CN 1552321A (publication number), put down in writing " purposes of Arbidol hydrochloride in preparation prevention and treatment SARS virus medicine " of Zhongqi Pharmaceutical Technology's invention
[14]It has medicinal application that significant inhibitory effect can be used as prevention and treatment SARS virus in clinical through cell in vitro experiment proof Arbidol hydrochloride to SARS virus.
In Chinese patent CN 101011389A (publication number), put down in writing " purposes of Arbidol hydrochloride in preparation prevention and treatment hepatitis B medicament " of Zhongqi Pharmaceutical Technology's invention
[15]It has medicinal application that significant inhibitory effect can be used as prevention and treatment hepatitis B in clinical through experiment in vitro proof Arbidol hydrochloride to hepatitis B.
In Chinese patent CN 1596892A (publication number), put down in writing " Arbidol hydrochloride is in the preparation prevention and treat the purposes in hepatitis B, the HIV virus drugs " of Zhongqi Pharmaceutical Technology's invention
[16]It has medicinal application that significant inhibitory effect can be used as prevention and treatment hepatitis B, HIV virus in clinical through experiment in vitro proof Arbidol hydrochloride to hepatitis B, HIV virus.
In Chinese patent CN 101461805A (publication number), put down in writing " a kind of purposes of anti-hantavirus medicament arbidol " of Wuhan University's invention
[17]It relates to a kind of new purposes of having invented the Arbidol hydrochloride anti-hantavirus.
Retrieve one piece through document and be published in 2006 the 26th volumes of Chinese Hospitals pharmaceutical journal the 4th phase the 397th page of article about " preparation of arbidol HCl micro emulsion and quality evalution thereof "
[18], put down in writing and adopted micro emulsion to prepare the method for oral Arbidol hydrochloride micro emulsion and it has been carried out quality evalution as pharmaceutical carrier.Different proportionings through different auxiliary material and organic solvent; Prepare in volumetry on the basis of pseudo-ternary phase diagram; According to the phasor optimizing prescriptions, investigated stability and the form particle diameter of micro emulsion prescription respectively, with high effective liquid chromatography for measuring the content of Arbidol hydrochloride in the micro emulsion.The result shows that the Arbidol hydrochloride micro emulsion is stable, is spheroidal under the transmission electron microscope, and being evenly distributed is the Gauss distribution, and the Arbidol hydrochloride content of high effective liquid chromatography for measuring is high, and method is reliable, good reproducibility.
Do not find the crystal formation report of relevant Arbidol hydrochloride hydrochloride through searching document and domestic and international patent.
There are essential difference in the present invention and existing patent or document; It is gone into a little is to start with from the research of the crystal-form substances existence of Arbidol hydrochloride hydrochloride monohydrate; Study through the polymorphic triage techniques; On the raw material aspect of active constituents of medicine, seek, find the new crystal kind and the status flag of Arbidol hydrochloride hydrochloride solid matter; And crystal formation research combined with healthcare applications with clinical, for seeking, discovery, developing Arbidol hydrochloride hydrochloride state the basic scientific research data are provided with optimal efficacy; Simultaneously, also for application country or international intellecture property invention patent protection provide scientific basis from Arbidol hydrochloride hydrochloride solid crystal formation raw material basis.
Summary of the invention
The technical problem that the present invention will solve provides a kind of new crystal formation of the Arbidol hydrochloride hydrochloride monohydrate shown in the formula (I), i.e. crystal B-type
Another technical problem that the present invention will solve provides the preparation method of Arbidol hydrochloride hydrochloride monohydrate crystal B-type material.
Another technical problem that the present invention will solve provides the product of Arbidol hydrochloride hydrochloride monohydrate crystal B-type composition as activeconstituents.
Another technical problem that the present invention will solve provides the application of Arbidol hydrochloride hydrochloride monohydrate crystal B-type.
Particularly, the technical problem for solving, adopt following technical scheme:
1. Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample morphological specificity:
1.1 Arbidol hydrochloride hydrochloride monohydrate crystal B-type state of matter, (CuK when using powder x-ray diffraction analysis
αRadiation), show as the Height%=100 peak position in 2-Theta=4.8 ± 0.2 ° or
The place and have 30 its positions of diffraction peak respectively 2-Theta (°) ± 0.2 ° of value or
Value has following expression:
And diffraction peak relative intensity value allows Height% ± 10% variation range (Fig. 1).
1.2 Arbidol hydrochloride hydrochloride monohydrate crystal B-type state of matter, its infrared absorption spectrum (Fig. 2) 3503,3322,3120,3058,2970,2897,2844,2590,1778,1675,1581,1503,1474,1463,1439,1424,1413,1383,1363,1324,1286,1256,1231,1197,1183,1162,1150,1130,1088,1054,1042,1024,1000,956,943,926,892,861,840,793,781,740,726,700,688,653cm
-1± 2cm
-1Absorption peak be the diffuse reflectance infrared spectroscopy peak position that Arbidol hydrochloride hydrochloride monohydrate crystal B-type solid matter is appeared.
1.3 Arbidol hydrochloride hydrochloride monohydrate crystal B-type state of matter, there are two Peak endotherm(ic)peaks in (Fig. 3) when being 10 ℃ of PMs when temperature rise rate in its DSC collection of illustrative plates, and transformation value is respectively at 134 ℃ ± 3 ℃ and 180 ℃ ± 3 ℃.
1.4 Arbidol hydrochloride hydrochloride monohydrate crystal B-type state of matter, its melting point values are 141 ℃ ± 2 ℃.
2. the preparation method characteristic of Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample:
2.1 the invention provides a kind of preparation method of Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample, go into certain water gaging and prepare Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample in adding after it is characterized in that using single methyl alcohol, acetone, acetonitrile, Virahol, ethanol, n-propyl alcohol, propyl carbinol, ETHYLE ACETATE, THF, dioxane, methylene dichloride, DMF, DMSO, chloroform, pyridine solvent under 10 ℃～80 ℃ temperature condition, the Arbidol hydrochloride hydrochloride sample to be dissolved fully through 10 ℃～80 ℃ of envrionment temperatures, ambient moisture 10%～75%, normal pressure or vacuum pressure condition.
2.2 the invention provides the preparation method of alternative Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample, go into certain water gaging and prepare Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample in adding after it is characterized in that using methyl alcohol, acetone, acetonitrile, Virahol, ethanol, n-propyl alcohol, propyl carbinol, ETHYLE ACETATE, THF, dioxane, methylene dichloride, DMF, DMSO, chloroform, pyridine two or more dissolving the Arbidol hydrochloride hydrochloride sample under 10 ℃～80 ℃ temperature condition by different proportioning mixed solvent systems fully arbitrarily through 10 ℃～80 ℃ of envrionment temperatures, ambient moisture 10%～75%, normal pressure or vacuum pressure condition.
3. Arbidol hydrochloride hydrochloride monohydrate crystal B-type is as the using dosage and the purposes characteristic of active substance:
3.1 of the present invention a kind of product is provided also, with Arbidol hydrochloride hydrochloride monohydrate crystal B-type composition as activeconstituents and contain other auxiliary materials.Product of the present invention comprises medicine, healthcare products.
The crystal formation purity of Arbidol hydrochloride hydrochloride monohydrate crystal B-type is 1%～100% in the described product.
The formulation of said product is selected from tablet, capsule, pill, injection, slowly-releasing or control-released agent, pulvis.
3.2 the invention provides the various product of Arbidol hydrochloride hydrochloride monohydrate crystal B-type material as the activeconstituents exploitation; Comprise medicine, healthcare products; It is characterized in that with Arbidol hydrochloride hydrochloride monohydrate crystal B-type material absorbing dosage its every day in 5mg～50g scope as activeconstituents.
3.3 the invention provides the various product of Arbidol hydrochloride hydrochloride monohydrate crystal B-type material as the activeconstituents exploitation; Comprise medicine, healthcare products, it is characterized in that using and contained Arbidol hydrochloride hydrochloride monohydrate crystal B-type material and guaranteed its in vivo absorption characteristic, effectively bioavailability, effective blood drug concentration, the stable time that continues and reach prevention, treatment, health-care effect and the application of making the most of the advantage as activeconstituents.
4. the absorption characteristic of Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample after oral:
The invention provides Arbidol hydrochloride hydrochloride monohydrate crystal B-type material as the activeconstituents development product; Comprise medicine and healthcare products; Biology sorption after the oral administration is characterized in that Arbidol hydrochloride hydrochloride monohydrate crystal B-type material brings into play prevention, treatment, health-care effect fast and have 12 hours with the upper mounting plate advantage function cycle through gi tract as activeconstituents after 2 minutes in blood.Accompanying drawing 4 provides Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample oral administration and absorbs the back at the intravital plasma concentration curve of rat.
5. the pharmaceutical applications of Arbidol hydrochloride hydrochloride monohydrate crystal B-type.
The invention provides the application of Arbidol hydrochloride hydrochloride monohydrate crystal B-type in preparation treatment antiviral.Preferred virus is selected from A, Type B influenza virus, SARS virus, hepatitis B, HIV virus, anti-hantavirus.
Description of drawings
The x-ray diffractogram of powder spectrum of Fig. 1 Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample
The infrared absorpting light spectra of Fig. 2 Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample
The DSC collection of illustrative plates of Fig. 3 Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample
Fig. 4 Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample oral administration absorbs the back at the intravital plasma concentration curve of rat
Embodiment
Be better explanation technical scheme of the present invention, the spy provides following examples, but the present invention is not limited to this.
The preparation method of Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample:
The preparation method of Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample; The water of going into equal volume in slowly adding after it is characterized in that using the 1L methanol solvate under 65 ℃ of reflux conditionss, 20g Arbidol hydrochloride hydrochloride sample to be dissolved fully can obtain Arbidol hydrochloride hydrochloride monohydrate crystal form samples in 65 ℃ of condition refluxed of temperature filtered while hot and with the gentle and quiet crystallization of putting of filtrate chamber after 3 hours.
The x-ray diffractogram of powder spectrum of gained Arbidol hydrochloride hydrochloride monohydrate crystal form samples is shown in accompanying drawing 1
The infrared absorpting light spectra of gained Arbidol hydrochloride hydrochloride monohydrate crystal form samples is shown in accompanying drawing 2
The DSC collection of illustrative plates of gained Arbidol hydrochloride hydrochloride monohydrate crystal form samples is shown in accompanying drawing 3
Above spectrum data result shows that present embodiment gained crystalline crystal formation is an Arbidol hydrochloride hydrochloride monohydrate crystal B-type.
The preparation method of Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample:
The preparation method of Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample; It is characterized in that adding volume ratio and be 1: 1 each 1L methyl alcohol and water mixed solvent with 20g Arbidol hydrochloride hydrochloride sample in 65 ℃ of temperature condition refluxed filtered while hot and with the gentle and quiet crystallization of putting of filtrate chamber after 3 hours;, can obtain Arbidol hydrochloride hydrochloride monohydrate crystal form samples.
The x-ray diffractogram of powder spectrum of gained Arbidol hydrochloride hydrochloride monohydrate crystal form samples is shown in accompanying drawing 1
The infrared absorpting light spectra of gained Arbidol hydrochloride hydrochloride monohydrate crystal form samples is shown in accompanying drawing 2
The DSC collection of illustrative plates of gained Arbidol hydrochloride hydrochloride monohydrate crystal form samples is shown in accompanying drawing 3
Above spectrum data result shows that present embodiment gained crystalline crystal formation is an Arbidol hydrochloride hydrochloride monohydrate crystal B-type.
The problem that needs explanation: since be used to prepare the single organic solvent of Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample total multiple, can be used to prepare two kinds of Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample or above solvent combinations and have over one hundred kind; Every kind of organic solvent boiling point value is different, different to Arbidol hydrochloride hydrochloride dissolving properties, variate-values such as the envrionment temperature of its experiment, humidity, time, pressure all there is some difference property and constant interval scope when causing under using different solvents condition preparation Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample.
Embodiment 3
Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample absorbs characteristic and Plasma Concentration characteristic in the rat body:
Laboratory animal is adopted the SD male rat of body weight 210 ± 20g; Normal condition is raised; Freely drink water; After the fasting 12 hours; Utilize solid delivery device (this laboratory patented product) to give Arbidol hydrochloride hydrochloride monohydrate crystal B-type medicine (pressing 300mg/kg dosage), respectively at the about 0.3mL of 0.03,0.08,0.25,0.5,1.0,2.0,3.0,4.0,6.0,8.0,10.0,12.0,24.0,36.0 (h) time point extracting vein blood (the ball rear vein beard is got blood) after the administration, the centrifugal 10min of 5000rpm; Get 150uL blood plasma, add 1mL ETHYLE ACETATE, vortex vibration 3min, the centrifugal 10min of 13400rpm gets supernatant 900uL, N
2Add 75uL moving phase after drying up and redissolve, vortex vibration 3min, the centrifugal 5min of 13400rpm gets supernatant 70uL and carries out the HPLC detection.The HPLC testing conditions: detection system is Agilent 1200, and chromatographic column is Agilent Eclipse TC-C
18(2), 250 * 4.6mm, 5um, moving phase is methyl alcohol: 1% triethylamine aqueous solution (pH=3.0)=67: 33, sample size are 30uL, and flow velocity is 1mL/min, and column temperature is 35 ℃, and the detection wavelength is 315nm.Detected result sees the following form.
Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample Plasma Concentration data
Experimental result shows: Arbidol hydrochloride hydrochloride monohydrate crystal B-type chemistry solid matter can be absorbed by rat; It is characterized in that to be absorbed after the administration of Arbidol hydrochloride hydrochloride monohydrate crystal B-type solid pharmaceutical oral administration, after 2 minutes, in blood, bring into play prevention, treatment, health-care effect fast and have 12 hours with the upper mounting plate advantage function cycle.Arbidol hydrochloride hydrochloride monohydrate crystal B-type material has guaranteed its in vivo absorption characteristic, effectively bioavailability, effective blood drug concentration, the stable time that continues and reach prevention, treatment, health-care effect and the application of making the most of the advantage as activeconstituents.
Arbidol hydrochloride hydrochloride monohydrate crystal B-type material is as the medicine dosage of activeconstituents:
The medicinal tablet or other preparations that use Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample to manufacture as active constituents of medicine; It is characterized in that containing the activeconstituents of Arbidol hydrochloride hydrochloride monohydrate crystal B-type as medicine; Every day, dosage was 300mg; Can be prepared into 3 times/each 1 100mg conventional tablet every day respectively, every day 2 times/each 1 150mg conventional tablet or every day 1 time/each 1 300mg the tablet type.
The problem that needs explanation: the Arbidol hydrochloride hydrochloride monohydrate crystal B-type pharmaceutical composition that the present invention relates to has many factor affecting on the dosage of effective constituent, for example: be used to prevent different with the purposes of treating and cause the difference of dosage every day; Ill character is different with ill severity and cause the different of dosage every day; The difference of patient's sex, age, body surface area, route of administration, administration number of times, therapeutic purpose are different and cause the difference of dosage every day; In addition, absorption that exists between crystal form samples and Plasma Concentration are not equal, and also causing the present invention is 0.01～200mg/kg body weight in appropriate dose scope every day of using Arbidol hydrochloride hydrochloride monohydrate crystal B-type composition, is preferably 1～100mg/kg body weight.Should formulate Arbidol hydrochloride hydrochloride monohydrate crystal B-type effective constituent total dose scheme according to the prevention of reality and treatment different situations demand during use, and can be divided into repeatedly or the single administration mode is accomplished.
Embodiment 5
Arbidol hydrochloride hydrochloride monohydrate crystal B-type material is as the healthcare products dosage of activeconstituents:
Use Arbidol hydrochloride hydrochloride monohydrate crystal B-type material as the functional health product that activeconstituents manufactures, it is characterized in that containing in the healthcare products Arbidol hydrochloride hydrochloride monohydrate crystal B-type as the health active component substances, its consumption is from 5mg～50g.
Reference
1.Boriskin?YS，Leneva?IA，Pécheur?EI，et?al.Arbidol：a?broad-spectrum?antiviral?compound?that?blocks?viral?fusion.Curr?Med?Chem.2008，15(10)：997-1005.
2.Shi?L，Xiong?H，He?J，et?al.Antiviral?activity?of?arbidol?against?influenza?A?virus，respiratory?syncytial?virus，rhinovirus，coxsackie?virus?and?adenovirus?in?vitro?and?in?vivo.Arch?Virol.2007，152(8)：1447-1455.
3. appoint rubine, Sun Jingxia, Jiang Hong, etc. the arbidol hydrochloride granule is at intravital pharmacokinetics of people and bioequivalence Journal of Sex Research [J]. Chinese Pharmaceutical Journal, 2006,41 (23): 1814-1817.
4. discipline twilight, Zhao Yanhong, Zhang Min, etc. the experiment in vitro research [J] of arbidol anti-SARS virus. PLA's medical journal, 2004,20 (4): 274-276.
5. Chinese patent, publication number CN 1589790A
6. Chinese patent, publication number CN 1868470A
7. Chinese patent, publication number CN 101904826A
8. Chinese patent, publication number CN 101653425A
9. Chinese patent, publication number CN 1792362A
10. Chinese patent, publication number CN 1535680A
11. Chinese patent, publication number CN 1572298A
12. Chinese patent, publication number CN 1839829A
13. Chinese patent, publication number CN 1546019A
14. Chinese patent, publication number CN 1552321A
15. Chinese patent, publication number CN 101011389A
16. Chinese patent, publication number CN 1596892A
17. Chinese patent, publication number CN 101461805A
18. the Chinese Hospitals pharmaceutical journal, 2006, the 26th volume, the 4th phase, the 397th page.
Claims (9)
1. the Arbidol hydrochloride hydrochloride monohydrate crystal B-type shown in the formula (I),
It is characterized in that (CuK when using powder x-ray diffraction analysis
αRadiation) show as the Height%=100 peak position in 2-Theta=4.8 ± 0.2 ° or
The place and have 30 its positions of diffraction peak respectively 2-Theta (°) ± 0.2 ° of value or
Value has following expression:
And diffraction peak relative intensity value allows Height% ± 10% variation range.
2. the preparation method of the Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample described in claim 1; It is characterized in that, go into certain water gaging and prepare Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample in adding after using single methyl alcohol, acetone, acetonitrile, Virahol, ethanol, n-propyl alcohol, propyl carbinol, ETHYLE ACETATE, THF, dioxane, methylene dichloride, DMF, DMSO, chloroform, pyridine solvent under 10 ℃～80 ℃ temperature condition, the Arbidol hydrochloride hydrochloride sample to be dissolved fully through 10 ℃～80 ℃ of envrionment temperatures, ambient moisture 10%～75%, normal pressure or vacuum pressure condition.
3. the preparation method of the Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample described in claim 1; It is characterized in that, go into certain water gaging and prepare Arbidol hydrochloride hydrochloride monohydrate crystal B-type sample in adding after using methyl alcohol, acetone, acetonitrile, Virahol, ethanol, n-propyl alcohol, propyl carbinol, ETHYLE ACETATE, THF, dioxane, methylene dichloride, DMF, DMSO, chloroform, pyridine two or more dissolving the Arbidol hydrochloride hydrochloride sample under 10 ℃～80 ℃ temperature condition by different proportioning mixed solvent systems fully arbitrarily through 10 ℃～80 ℃ of envrionment temperatures, ambient moisture 10%～75%, normal pressure or vacuum pressure condition.
4. a product is characterized in that, as activeconstituents, and contains other auxiliary materials with the described Arbidol hydrochloride hydrochloride monohydrate of claim 1 crystal B-type composition.
5. according to the product of claim 4, it is characterized in that the crystal formation purity of described Arbidol hydrochloride hydrochloride monohydrate crystal B-type is 1%～100%.
6. according to the product of claim 4, it is characterized in that said product is selected from medicine, healthcare products.
7. according to each product among the claim 4-6, the formulation of said product is selected from tablet, capsule, pill, injection, slowly-releasing or control-released agent, pulvis.
8. the application of the Arbidol hydrochloride hydrochloride monohydrate crystal B-type of claim 1 in preparation treatment antiviral.
9. according to Claim 8 application, described virus are selected from A, Type B influenza virus, SARS virus, hepatitis B, HIV virus, anti-hantavirus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110128507.1A CN102786462B (en) | 2011-05-18 | 2011-05-18 | Arbidol hydrochloride crystal B-type and preparation method are applied with in medicine and health product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110128507.1A CN102786462B (en) | 2011-05-18 | 2011-05-18 | Arbidol hydrochloride crystal B-type and preparation method are applied with in medicine and health product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102786462A true CN102786462A (en) | 2012-11-21 |
| CN102786462B CN102786462B (en) | 2016-08-31 |
Family
ID=47152070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110128507.1A Active CN102786462B (en) | 2011-05-18 | 2011-05-18 | Arbidol hydrochloride crystal B-type and preparation method are applied with in medicine and health product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102786462B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106366029A (en) * | 2016-08-19 | 2017-02-01 | 江苏吴中医药集团有限公司苏州制药厂 | Arbidol mesylate monohydrate crystal C and its preparation method and use |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198552A (en) * | 1989-01-12 | 1993-03-30 | Trofimov Fedor A | Indole derivative having antiviral, interferon-inducing and immunomodulatory effects |
| RU2008004C1 (en) * | 1986-06-25 | 1994-02-28 | Центр по химии лекарственных средств - ВНИХФИ | Prophylactic and curative agent for treating flu virus b |
| CN1687033A (en) * | 2005-04-26 | 2005-10-26 | 武汉大学 | Medication for anti virus of respiratory tract and application |
| CN101084892A (en) * | 2005-04-26 | 2007-12-12 | 武汉大学 | Anti-respiratory virus medicine and use |
| CN101084893A (en) * | 2005-04-26 | 2007-12-12 | 武汉大学 | Anti-respiratory virus medicine and use |
| US20090326037A1 (en) * | 2005-12-28 | 2009-12-31 | Irina Anatolievna Leneva | Medicinal Agent For Treating Viral Infections |
| CN101653425A (en) * | 2009-09-15 | 2010-02-24 | 山东罗欣药业股份有限公司 | Arbidol hydrochloride medicament composition dispersible tablets and preparation method thereof |
-
2011
- 2011-05-18 CN CN201110128507.1A patent/CN102786462B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008004C1 (en) * | 1986-06-25 | 1994-02-28 | Центр по химии лекарственных средств - ВНИХФИ | Prophylactic and curative agent for treating flu virus b |
| US5198552A (en) * | 1989-01-12 | 1993-03-30 | Trofimov Fedor A | Indole derivative having antiviral, interferon-inducing and immunomodulatory effects |
| CN1687033A (en) * | 2005-04-26 | 2005-10-26 | 武汉大学 | Medication for anti virus of respiratory tract and application |
| CN101084892A (en) * | 2005-04-26 | 2007-12-12 | 武汉大学 | Anti-respiratory virus medicine and use |
| CN101084893A (en) * | 2005-04-26 | 2007-12-12 | 武汉大学 | Anti-respiratory virus medicine and use |
| US20090326037A1 (en) * | 2005-12-28 | 2009-12-31 | Irina Anatolievna Leneva | Medicinal Agent For Treating Viral Infections |
| CN101653425A (en) * | 2009-09-15 | 2010-02-24 | 山东罗欣药业股份有限公司 | Arbidol hydrochloride medicament composition dispersible tablets and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| TROFIMOV F.A.,等: "Synthesis of the new antiviral drug Arbidol", 《KHIM-FARM ZH》, vol. 27, no. 1, 31 December 1993 (1993-12-31), pages 70 - 71 * |
| VLADIMIR V. CHERNYSHEV,等: "Structural characterization of arbidol", 《ZEITSCHRIFT FUER KRISTALLOGRAPHIE - CRYSTALLINE MATERIALS》, vol. 226, no. 11, 31 December 2011 (2011-12-31), pages 832 - 836 * |
| 吴秀静: "抗流感病毒药阿比朵尔及其衍生物的合成研究", 《沈阳药科大学硕士学位论文》, 15 March 2004 (2004-03-15), pages 32 * |
| 温艳珍,等: "盐酸阿比朵尔的合成路线图解", 《中国医药工业杂志》, vol. 37, no. 12, 10 December 2006 (2006-12-10), pages 862 - 864 * |
| 王钝,等: "盐酸阿比朵尔的合成", 《中国医药工业杂志》, vol. 35, no. 08, 20 August 2004 (2004-08-20), pages 457 - 458 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106366029A (en) * | 2016-08-19 | 2017-02-01 | 江苏吴中医药集团有限公司苏州制药厂 | Arbidol mesylate monohydrate crystal C and its preparation method and use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102786462B (en) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101461949B (en) | Berberine cyclodextrin inclusion compound, preparation thereof and preparation method | |
| CN102423346B (en) | A kind of Cortex Moutan extract and its production and use | |
| CN104016978B (en) | Palmatine hydrochloride crystal form C as well as preparation method thereof and application thereof in medicament composition or health-care product | |
| CN109232293A (en) | Fragrant happy amine crystalline substance G type, preparation method and its composition and purposes | |
| CN102786573B (en) | Glycyrrhetinic acid crystal B-type material and preparation method and apply in medicine and healthcare products | |
| CN102786519B (en) | Praziquantel crystal B substance, its preparation method and its applications in medicines and healthcare products | |
| CN102786462A (en) | Arbidol hydrochloride crystal B, its preparation method, and its applications in medicines and healthcare products | |
| CN102786518B (en) | Palmatine hydrochloride crystal B-type material and preparation method are applied with in medicine and health product | |
| CN114644642B (en) | Crystal form A of thienopyridine compound, preparation method and pharmaceutical composition thereof | |
| CN102786520A (en) | Praziquantel crystal A substance, its preparation method and its applications in medicines and healthcare products | |
| CN102786461A (en) | Arbidol hydrochloride crystal E, its preparation method and its applications in medicines and healthcare products | |
| Oderinlo et al. | Acridone alkaloids: in-silico investigation against SARS-CoV-2 main protease | |
| CN103816147A (en) | Novel pharmaceutical uses of garcinolic acid, neogambogic acid and composition of garcinolic acid and neogambogic acid | |
| CN103864776B (en) | A kind of Tegafur derivative containing 1,3,4-thiadiazoles heterocycle and amide group | |
| CN107245054A (en) | A kind of amorphous bulleyaconitine A compound and preparation method thereof | |
| CN1857400A (en) | Coated selfheal tablet and its preparing method | |
| CN109232297A (en) | Fragrant happy amine crystal B-type, preparation method and its composition and purposes | |
| CN106632373A (en) | A D crystal form solid substance of bergenin, a preparing method thereof and uses of the substance | |
| CN102670698B (en) | The application of Radix Flemingiae Philippinensis extract in preparation control diabetes medicament | |
| CN104098567B (en) | Diprophylline crystalline substance II types material and preparation method and its pharmaceutical composition and purposes | |
| CN102786521B (en) | Risperidone brilliant type III material and preparation method and apply in medicine and healthcare products | |
| CN102786574A (en) | Glycyrrhetinic acid crystal A substance, its preparation method, and its applications in medicines and healthcare products | |
| CN100448450C (en) | Pharyngolaryngitis-treating pharmaceutical compositions and its preparing method | |
| CN105753869B (en) | A kind of eutectic and preparation method thereof of CDK inhibitor and mek inhibitor | |
| CN103130853B (en) | Roxithromycin (ROX) crystal C type matter, preparation method thereof, medicine composition thereof and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |